Sorbact® is a registered trademark owned by ABIGO Medical ABlogo
Sorbact® advantages

Effective wound healing

Safe and effective removal of bacteria reduces the bioburden in wounds which facilitates the healing process. It is also shown that Sorbact® exhibits high cell compatibility and does not change cell morphology. Moreover there is a minimized cell attachment to the dressing surface which thereby increases safety towards tissues.

No contraindications and low risk of allergies

Reduces the bioburden in wounds1, 2

Immediate onset of action3

Development of bacterial resistance is not expected

No release of active agents into the wound4

Suitable for prolonged treatment

Does not promote the bacterial release of endotoxins5

Binds common microbes in the wound
– as well as multi-resistant bacteria

Common wound microorganisms, such as Staphylococcus aureus, Streptococcus species, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, bind to the unique surface of Sorbact®.* Sorbact® also binds MRSA (methicillin-resistant Staphylococcus aureus)6, VRE (Vancomycin-Resistant Enterococcus) and targets fungi.

*In vitro data

No known bacterial resistance

With the Sorbact® mode of action, unlike certain antimicrobial substances that kill microbes, development of bacterial or fungal resistance is not expected, and it can be used for a prolonged period of time.

Facilitates wound healing

Elevated microbe levels will result in risk of infection and delayed wound healing. Sorbact® safely reduces the bioburden thus improving the conditions for efficient wound healing.

Sorbact® can be used to prevent and treat wound infections and in conjunction with systemic antibiotic therapy if needed.

References

1.Gentili V, Gianesini S, et al. 2012. Panbacterial real-time PCR to evaluate bacterial burden in chronic wounds treated with Cutimed Sorbact. Eur J Clin Microbiol Infect Dis. 31(7):1523-1529link
2.Mosti G, Magliaro A, et al. 2015. Comparative study of two antimicrobial dressings in infected leg ulcers: a pilot study. J Wound Care. 24(3):121-122, 124-127.link
3.Data on file, a. ABIGO Medical
4.Data on file, b. ABIGO Medical
5.Budi Susilo Y and Husmark J. DACC coated wound dressing and endotoxin: Investigation on binding ability and effect on endotoxin release from gram-negative bacteria. EWMA 2019. 2019;EP167.
6.Ronner AC, Curtin J, et al. 2014. Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings. J Wound Care. 23(10):484, 486-488. link

Unsupported browser

This site probably won't work great in Internet Explorer. We generally only support the recent versions of major browsers like Chrome, Firefox, Safari and Edge.